1. Design and in vivo evaluation of a microparticulate depot formulation of buprenorphine for veterinary use.
- Author
-
Schreiner, Viktoria, Durst, Mattea, Arras, Margarete, Detampel, Pascal, Jirkof, Paulin, and Huwyler, Jörg
- Subjects
- *
BUPRENORPHINE , *ANALGESICS , *VETERINARY medicine , *PAIN management , *LABORATORY mice - Abstract
Buprenorphine is a frequently used analgetic agent in veterinary medicine. A major drawback, however, is the short duration of action requiring several daily administrations. We therefore designed a poly-lactic-co-glycolic acid (PLGA) based microparticulate drug formulation for sustained parenteral drug release. Particles were designed to allow for a fast onset of action and a duration of the analgesic effect of at least two days in laboratory mice. Microparticles were produced using a solvent evaporation technique. Release rate was dependent on polymer type and particle size. Spherical particles used for subsequent animal studies had a mean size of 50 µm and contained 4.5% of buprenorphine. Drug release was characterized by an initial burst release of 30% followed by complete release over seven days. In vivo pharmacokinetic experiments in female C57BL/6 J mice confirmed prolonged exposure in plasma and brain tissue and correlated with the pharmacological effect in the hot plate assay or after minor abdominal surgery. No adverse side effects with respect to food and water intake, body weight, local tolerability, or nesting behavior were observed. Our formulation is an attractive alternative to established immediate release formulations. A use for prolonged pain management in laboratory animals is proposed. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF